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for αv integrins in regulatory  
T cell accumulation at sites  
of inflammation
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Melanie D. Leech, Danielle J. Smyth, Richard A. O’Connor, Neil C. Henderson  
and Stephen M. Anderton*
MRC Centre for Inflammation Research, Centre for Multiple Sclerosis Research, BHF Centre for Cardiovascular Science, and 
Centre for Immunity Infection and Evolution, University of Edinburgh, Edinburgh, United Kingdom
Several inflammatory diseases including multiple sclerosis and inflammatory bowel disease 
have been associated with dysfunctional and/or reduced numbers of Foxp3+ regulatory 
T cells (Treg). While numerous mechanisms of action have been discovered by which 
Treg can exert their function, disease-specific Treg requirements remain largely unknown. 
We found that the integrin αv, which can pair with several β subunits including β8, is 
highly upregulated in Treg at sites of inflammation. Using mice that lacked αv expression 
or β8 expression specifically in Treg, we demonstrate that there was no deficit in Treg 
accumulation in the central nervous system during experimental autoimmune enceph-
alomyelitis and no difference in the resolution of disease compared to control mice. In 
contrast, during a curative T cell transfer model of colitis, Treg lacking all αv integrins were 
found at reduced proportions and numbers in the inflamed gut. This led to a quantitative 
impairment in the ability of αv-deficient Treg to reverse disease when Treg numbers in the 
inflamed colon were below a threshold. Increase of the number of curative Treg injected 
was able to rescue this phenotype, indicating that αv integrins were not required for 
the immunosuppressive function of Treg per se. In accordance with this, αv deficiency 
did not impact on the capacity of Treg to suppress proliferation of naive conventional 
T cells in vitro as well as in vivo. These observations demonstrate that despite the general 
upregulation of αv integrins in Treg at sites of inflammation, they are relevant for adequate 
Treg accumulation only in specific disease settings. The understanding of disease-specific 
mechanisms of action by Treg has clear implications for Treg-targeted therapies.
Keywords: integrin αv, Foxp3, regulatory T cell, experimental autoimmune encephalomyelitis, colitis, autoimmune 
disease, inflammation, resolution of inflammation
inTrODUcTiOn
Regulatory T cells (Treg) are a major target in the search for novel therapies for immune-mediated 
diseases—both through pharmacological manipulation and cell-based therapies (1, 2). They display 
a plethora of mechanisms by which they can mediate immune suppression, including cytolysis, 
modulation of antigen presenting cells, metabolic disruption, and secretion of inhibitory cytokines 
Abbreviations: CNS, central nervous system; DC, dendritic cell; EAE, experimental autoimmune encephalomyelitis; iLN, 
inguinal lymph node; LP, lamina propria; mLN, mesenteric lymph node; pMOG, 35–55 peptide of mouse myelin oligoden-
drocyte glycoprotein; pOVA, ovalbumin peptide 323–339; Tn, naive CD4+ T cells; Treg, regulatory T cells; WT, wild-type.
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such as TGF-β, IL-10, and IL-35 (3). Treg are responsible for the 
inhibition of inadequate T cell activation in secondary lymphoid 
organs, but also migrate to inflamed sites to control ongoing 
inflammation. In order to optimally target Treg, it is important to 
understand how Treg are recruited to sites of inflammation and 
which suppressive mechanisms they deploy, which may well be 
dictated in organ- or disease-specific manners (4–9).
Most circulating Treg display a phenotype resembling that 
of naive conventional T cells and have been coined central Treg 
(10). Central Treg are thought to be important in preventing 
the activation of autoreactive T cells by antigen-presenting cells 
in secondary lymphoid organs (11). However, a small fraction 
of circulating Treg displays an activated phenotype and shows 
enhanced migration through non-lymphoid tissue. The homeo-
static requirements of these so-called effector Treg are poorly 
understood, but at least some populations appear to be IL-2 
independent (10, 12, 13). The surface expression of chemokine 
receptors (10, 14–16), as well as integrins such as αE (17, 18), 
αL (19), and β7 (5) has been shown to define Treg migration to 
specific sites.
Integrins, consisting of an α and a β subunit, are important 
players in cell adhesive functions and motility, but are also involved 
in intracellular signaling modulating cell survival, proliferation 
and differentiation (20). αv integrins (αvβ1, αvβ3, αvβ5, αvβ6, 
αvβ8) all recognize the RGD tripeptide sequence found in several 
components of the extracellular matrix as well as latent TGF-β 
(21, 22) and have recently been associated with important func-
tions in several immune cells. αvβ1 and αvβ3 have been linked to 
interstitial migration of CD4+ effector T cells (23) and αvβ8 has 
been shown to be the key driver for TGF-β activation by CD103+ 
dendritic cells (DCs) and thereby immune homeostasis in the gut 
(24–26). Recently, the integrin αvβ8 has also been implicated in 
activation of latent TGF-β by Treg (27, 28). However, their com-
mon binding site would suggest that redundancy is highly likely 
between αv integrins.
On this point, the contribution of αv integrins other than 
αvβ8 to Treg function in homeostatic or inflammatory settings 
is unknown. Using conditional knockout mice lacking either all 
αv integrins or only the integrin αvβ8, we investigated the role of 
αv integrins in Treg function under inflammatory conditions. We 
found that αv integrins (but not specifically αvβ8) were required 
for efficient Treg accumulation in the inflamed intestine and reso-
lution of inflammation, but had no role in Treg activity during 
central nervous system (CNS) inflammation.
MaTerials anD MeThODs
Mice, antigens, and Tissue culture 
Medium
All mice used were on the I-Ab background. Rag1−/− mice and 
congenically identifiable (CD45.1) OT-II transgenic mice with a 
TCR reactive toward ovalbumin peptide 323–339 (pOVA) (29) 
were maintained at the University of Edinburgh. Foxp3tm4(YFP/cre)Ayr  
mice (30) were kindly provided by Dr. A. Rudensky. Itgavfl/fl 
mice (25) were crossed with Foxp3tm4(YFP/cre)Ayr mice to generate 
conditional Foxp3-αv−/− mice. Similarly, Itgb8fl/fl mice (31) were 
crossed with Foxp3tm4(YFP/cre)Ayr mice to generate conditional 
Foxp3-β8−/− mice. Conditional knockout mice were screened by 
PCR assessing the presence of the floxed αv or β8 gene, respec-
tively, and the presence of the CRE gene. These lines expressed 
YFP under control of the Foxp3 promoter. All mice were bred 
under specific pathogen-free conditions at the University of 
Edinburgh. All experiments were approved by the University of 
Edinburgh Ethical Review Committee and were performed in 
accordance with UK legislation. The pOVA peptide and the 35–55 
peptide of mouse myelin oligodendrocyte glycoprotein (pMOG) 
were obtained from Cambridge Research Biochemicals (Teesside, 
UK). Tissue culture medium (RPMI 1640 medium) was supple-
mented with 2 mM l-glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 50 µM 2-ME (all from Gibco, Paisley, UK) plus 
10% FCS (Labtech, East Sussex, UK).
cell Purification and culture
CD4+ T  cells were purified by magnetic cell sorting (Miltenyi 
Biotec, Germany) prior to surface staining and sorting by FACS. 
CD4+YFP-CD62Lhi naive T cells from Foxp3tm4(YFP/cre)Ayr mice were 
used as responder T cells for in vitro suppression assays as well 
as disease-inducing cells in the T  cell transfer colitis models. 
CD4+YFP-CD62Lhi naive T  cells from Foxp3tm4(YFP/cre)Ayr, Foxp3-
αv−/− or Foxp3-β8−/− mice were also used as starting populations 
for induced Treg (iTreg) generation as previously described (32). 
CD4+YFP+ nTreg were isolated from Foxp3tm4(YFP/cre)Ayr, Foxp3-
αv−/− or Foxp3-β8−/− mice and tested for their suppressive capacity 
in in vitro suppression assays or in T cell transfer colitis models. 
In vitro stimulation was provided by anti-CD3e (clone 145.2C11; 
eBioscience, Hatfield, UK) plus anti-CD28 (clone 37.51; eBiosci-
ence) at 2 µg/ml each. Cell culture supernatants were tested for 
IL-10 concentrations using a mouse IL-10 ELISA kit according to 
manufacturer’s instructions (eBioscience).
In Vitro suppression assay
Suppression assays were performed by culturing CD4+YFP-
CD62Lhi naive responder T  cells (2  ×  104/well) for 96  h with 
increasing numbers of CD4+YFP+ nTreg from Foxp3 reporter 
mouse lines (0–2 × 104/well) in the presence of irradiated (30 Gray) 
splenic APCs and 1 µg/ml anti-CD3e. For the last 16 h of culture, 
0.25 μCi of 3H-thymidine (Amersham Biosciences, Amersham, 
UK) was added to each well and incorporation determined as 
mean counts per minute (cpm) using a β-scintillation counter 
(Wallac, Turku, Finland).
In Vivo Priming
Host mice (CD45.2) received 2 × 106 CD4+ OT-II T cells (CD45.1) 
i.v. 1 day prior to immunization with 20 µg pOVA emulsified in 
complete Freund’s adjuvant (CFA, containing 200 µg heat-killed 
Mycobacterium tuberculosis H37Ra) (Sigma) in a final volume 
of 100 µl. Seven days after immunization, spleens and draining 
lymph nodes were isolated for flow cytometric analysis.
induction of experimental autoimmune 
encephalomyelitis (eae)
Mice were immunized by subcutaneous injection of 100  µg 
pMOG, emulsified in CFA in a final volume of 100  µl. Mice 
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received 200–250 ng of Pertussis toxin in 500 µl PBS i.p. on the 
same day as immunization and 2 days later (33). Clinical signs 
of EAE were scored daily using the following scoring system; 
0, no signs; 1, flaccid tail; 2, impaired righting reflex and/or 
gait; 2.5, impaired gait including notable but intermittent drag-
ging of feet; 3, partial hind limb paralysis; 4, total hind limb 
paralysis; 5, hind limb paralysis with partial forelimb paralysis; 
6, moribund or dead. Mice were sacrificed by CO2 asphyxiation 
at the latest 30 days after disease induction, or at an earlier time 
point to isolate organs for analysis. Assessment of CNS (brain 
and spinal cord) immune cells was conducted as described 
previously (34).
T cell Transfer colitis
Preventive model of T  cell transfer colitis; RAG1−/− mice were 
injected i.v. with PBS or 5 × 105 naive wild-type (WT) CD4+ T cells 
(CD4+CD62LhiYFP-) from Foxp3tm4(YFP/cre)Ayr mice in the presence 
or absence of 1.5 × 105 nTreg (CD4+YFP+) from Foxp3tm4(YFP/cre)Ayr 
or Foxp3-αv−/− mice in a total volume of 200 µl.
Curative model of T  cell transfer colitis; RAG1−/− mice 
were injected i.v. with PBS or 5  ×  105 naive WT CD4+ T  cells 
(CD4+CD62LhiYFP-) from Foxp3tm4(YFP/cre)Ayr mice, followed by i.v. 
injection of 2.5–8 × 105 nTreg (CD4+YFP+) from the indicated 
Foxp3 reporter mice 21  days later. Mice were monitored daily 
and weighed three times a week until cull at 6–9 weeks after naive 
T  cell transfer for analysis of spleen, mesenteric lymph nodes 
(MLNs), and colons. One half of the colonic tissue was used to 
isolate lymphoid cells from the lamina propria (LP). Briefly, the 
intestinal epithelial layer was removed by incubation in HBSS 
2 mM EDTA for 30 min, and the remaining tissue digested with 
1.25 mg/ml collagenase-4 (Worthington) and 30 µg/ml DNase-1 
(Roche) in culture medium and disaggregated with a gentle 
MACS dissociator (Miltenyi). Retrieved lymphoid cells were 
stained and analyzed by flow cytometry. The other half of colonic 
tissue was processed for staining by hematoxylin and eosin 
and assessed for colitis severity in a blinded fashion using the 
following scoring system for a maximum of 11 points; mucosal 
infiltration (0-3); submucosal infiltration (0-3); crypt loss (0-3); 
crypt abscesses (0-2).
antibodies and Facs analysis
Cells were stained with the following antibodies (all from eBio-
science, except where stated); anti-CD4-BV650 (BioLegend, 
San Diego, CA, USA), anti-Foxp3-(ef450/FITC), anti-CD11b-
AF700 (Biolegend), anti-αv-PE, anti-CD44-APC-Cy7, anti-
CD62L-PerCP-Cy5.5, anti-Ki-67-PE-Cy7, anti-KLRG1-ef450, 
anti-CD45.1-APC, anti-CD51-PE, anti-GM-CSF-PE, anti-IFN-
γ-APC, anti-IL-17-PerCPCy5.5. Rat IgG2a and rat IgG1, conju-
gated to respective fluorophores, were used as isotype control 
antibodies. For intracellular cytokine staining, cells were re-
stimulated ex vivo with 20 µg/ml pOVA overnight, and Brefeldin 
A added for the last 4  h of incubation. Samples were stained 
with a fixable viability marker (conjugated with eFluor455, 
eBioscience) prior to surface staining. For subsequent intracel-
lular antigen staining, samples were washed once in FACS buffer 
(PBS, 2% FCS, 0.01% NaN3) and then processed according to 
manufacturer’s instructions (eBioscience for transcription 
factors, BD for intracellular cytokines). Flow cytometric data 
were acquired using a BD LSR Fortessa cell analyzer (BD) and 
data analyzed using FlowJo software (Treestar version 3.2.1, 
Ashland, OR, USA).
immunohistochemistry
Paraffin-embedded longitudinal sections of the gut were cleared 
and rehydrated in xylene and graded alcohols, followed by anti-
gen retrieval through pressure boiling in citrate buffer (Vector, 
Burlingame, CA, USA). Endogenous peroxidase activity was 
blocked with 3% H2O2 (Fisher Scientific) in dH2O, 10% normal 
goat serum (Biosera, Boussens, France) in PBS was used to 
block unspecific binding sites, and endogenous avidin/biotin 
was blocked using an avidin-biotin blocking kit according to 
manufacturer’s instructions (Vector). Samples were stained with 
biotinylated rat anti-mouse Foxp3 antibody (eBioscience, clone 
FJK-16s) and purified rabbit anti-mouse CD3 antibody (Abcam, 
polyclonal). Samples were then incubated with streptavidin-
coupled alkaline phosphatase (Vector) for 1 h at room tempera-
ture, washed, and Vector Blue substrate (SK-5300, Vector) added 
according to manufacturer’s instructions. Samples were subse-
quently incubated with horseradish peroxidase-coupled goat 
anti-rabbit antibody, washed, and DAB working solution added 
according to manufacturer’s instructions (Vector). Slides were 
mounted in Permafluor mounting medium (Thermo Scientific) 
prior to digitalization with an Axioscan.Z1 slide scanner (Carl 
Zeiss).
statistical analysis
Statistical analyses were performed using GraphPad Prism 
software (San Diego, CA, USA). In order to verify that data 
were normally distributed, Shapiro–Wilk normality tests were 
conducted. In experiments where data followed a Gaussian 
distribution, significance was tested using an unpaired Student’s 
t-test when comparing two experimental groups, and a one-way 
ANOVA with Bonferroni’s post hoc test when comparing three or 
more experimental groups. When n numbers were not sufficient 
to test for normality, or when data proved not to be normally 
distributed, the non-parametric Mann–Whitney test (compar-
ing two groups) or the non-parametric Kruskal–Wallis test with 
Dunn’s post hoc test (three or more groups) were applied. Due 
to the ranked nature of EAE disease scores and disease length, 
the non-parametric Kruskal–Wallis test with Dunn’s post hoc test 
was used to determine differences between three or more groups. 
When examining the effect of two factors on the experimental 
outcome, a two-way ANOVA was applied with Bonferroni’s 
post hoc test where applicable. Data were considered significantly 
different with p-values of <0.05 (*p  <  0.05, **p  <  0.01, and 
***p < 0.001).
resUlTs
Treg at sites of inflammation express  
high levels of the integrin αv
Experimental autoimmune encephalomyelitis is a useful expe-
rimental model to compare the function and behavior of CD4+ 
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T cells, including Treg, retrieved from the site of autoimmune 
inflammation (in this case the CNS) versus those from the sec-
ondary lymphoid organs of the same mouse. We have previously 
documented that Treg retrieved from the inflamed CNS display 
a suppressive potency that is markedly superior to that of their 
splenic counterparts (35). Here, we sought to understand any 
causative association between this elevated Treg function and 
their expression of αv integrins. Treg retrieved from the inflamed 
CNS shortly after peak of disease (Figures  1A,B) exhibited 
markedly higher surface αv expression levels compared to Treg 
in the spleen and inguinal lymph nodes (iLNs) (Figures 1C,D). 
Treg surface αv expression levels were also higher compared 
to effector T cells, in both spleen and CNS (Figure 1D). These 
differences were confirmed at the mRNA level using qPCR of 
sorted CD4+ T cell populations (Figure 1E).
To understand whether increased αv expression was a more 
general feature of Treg exposed to inflammation, we investi-
gated αv expression patterns in a curative T cell transfer model 
of colitis. Treg were injected into RAG1−/− mice 3 weeks after 
disease induction and colon LP, mLNs, and spleen harvested 
6  weeks later (Figures  1F,G). Following an initial weight loss 
typical for T cell induced colitis, mice treated with Treg started 
regaining weight about 1  week post-Treg injection, indicative 
of the immunosuppressive activity of the injected Treg. Again, 
Treg found in the colon LP expressed αv at markedly higher 
levels than their splenic and mLN counterparts, as well as their 
Foxp3− counterparts (Figures 1H,I), suggesting that Treg at sites 
of inflammation may generally exhibit enhanced αv expression 
levels.
Treg homeostasis is not Dependent  
on αv integrins
In order to test whether αv integrins are required by Treg to 
maintain immune homeostasis, we generated conditional 
Foxp3-αv−/− mice lacking αv specifically in Foxp3+ cells by 
crossing Foxp3tm4(YFP/cre)Ayr mice (30) with Itgavfl/fl mice (25). Both 
naive CD4+ T cells and Treg from Foxp3tm4(YFP/cre)Ayr control mice 
expressed αv (Figure  2A). As expected, surface αv expression 
was absent specifically among Treg from Foxp3-αv−/− mice 
(Figures  2A,B). Importantly, proportions of Treg in spleen, 
lymph nodes and colon LP remained unaltered in the absence of 
Treg αv integrins (Figure 2C), indicating that αv integrins are not 
involved in Treg maturation and homeostasis. Treg from Foxp3-
αv−/− mice and Foxp3tm4(YFP/cre)Ayr control mice displayed compa-
rable CD62L and CD44 expression in the steady state, indicating 
unaltered activation status in the absence of αv integrins (Figure 
S1A in Supplementary Material). Similarly, Ki-67 levels were 
indistinguishable between control and αv−/− nTreg, suggesting 
no alteration in cell cycle progression and hence proliferative 
potential in these cells (Figure S1B in Supplementary Material). 
Foxp3 expression levels within the Foxp3+ Treg pool were also 
comparable between control and Foxp3-αv−/− mice (Figure S1C 
in Supplementary Material).
In order to verify that the deletion of the Itgav gene occurred 
upon induction of Foxp3, iTreg were generated from naive CD4+ 
T  cells of Foxp3tm4(YFP/cre)Ayr control and Foxp3-αv−/− mice for 
5 days. >50% of naive CD4+ T cells in both groups expressed αv at 
the start of culture. At the end of culture, >95% of the cells in both 
groups expressed Foxp3 (Figure 2D). Surprisingly, αv expression 
was downregulated on all cells over the course of 5 days in iTreg 
culture (Figure  2E). However, upon replenishment of culture 
media without TGF-β for 2 days, control iTreg readily recovered 
αv expression, while Foxp3-αv−/− iTreg were unable to do so 
(Figure 2E). This demonstrated that the ability to express αv in 
CD4+ T cells was lost upon Foxp3 induction in these conditional 
knockout mice.
Considering the marked impact of iTreg culture conditions 
on αv expression in these cells, this phenomenon was further 
examined. Stimulation of naive T cells, in the absence of active 
TGF-β, did not result in a loss of αv expression (Figure S1D in 
Supplementary Material), suggesting that the presence of active 
TGF-β during culture caused downregulation of αv. Since stimu-
lation of naive T cells in the presence of TGF-β led to reduced 
αv expression even in CD4+ T cells not expressing Foxp3 within 
5  days (Figure S1E in Supplementary Material), downregula-
tion of αv was unlikely a secondary effect of Foxp3 induction. 
A similar effect was observed in nTreg, whereby nTreg stimulated 
in the presence of active TGF-β for 3 days displayed significantly 
lower levels of αv compared to nTreg stimulated in the absence 
of active TGF-β (Figure S1F in Supplementary Material). Loss 
of surface αv through the presence of TGF-β was partially pre-
vented by the addition of a TGF-β type I receptor (ALK5) kinase 
inhibitor, supporting the idea that TGF-β signaling itself led to 
αv downregulation.
Treg Do not require αv expression in 
Order to suppress the activation and 
Proliferation of conventional T cells
Conventional CD4+ T cells in spleen, iLN, mLN, and colon LP of 
Foxp3tm4(YFP/cre)Ayr control mice and Foxp3-αv−/− mice displayed a 
similar activation status and proliferative activity (Figures S2A,B 
in Supplementary Material), indicating normal Treg activity in 
the absence of αv integrins under steady state. Indeed, Foxp3-
αv−/− mice did not develop a spontaneous inflammatory disorder 
when left to age up to 10 months (data not shown). Consistent 
with this, no differences were found in the ability of nTreg from 
αv−/− or Foxp3tm4(YFP/cre)Ayr mice to inhibit responder T cell prolif-
eration using an in vitro suppression assay (Figure 3A). Likewise, 
iTreg generated from Foxp3-αv−/− mice showed no impairment 
in suppressive activity in vitro (data not shown). The secretion 
of IL-10, a major Treg-derived immunosuppressive cytokine, 
was also not impaired in αv−/− Treg upon in  vitro stimulation 
(Figure 3B).
To test Treg suppressive function in  vivo, Foxp3-αv−/− and 
Foxp3tm4(YFP/cre)Ayr control mice were seeded with CD4+CD45.1+ 
T  cells from OT-II mice prior to immunization with pOVA. 
Proportions and total numbers of CD45.1+ donor cells that 
had subsequently accumulated in the spleen or draining lymph 
nodes did not differ between Foxp3-αv−/− and control mice 
(Figures 3C,D, data not shown). Also, no difference was observed 
in donor cell activation and proliferation status (Figures S3A,B 
in Supplementary Material), and pro-inflammatory cytokine 
FigUre 1 | αv is highly expressed on regulatory T cells (Treg) at sites of inflammation experimental autoimmune encephalomyelitis (EAE) was induced in 
Foxp3tm4(YFP/cre)Ayr mice by immunization with 35–55 peptide of mouse myelin oligodendrocyte glycoprotein (pMOG), and spleen, inguinal lymph nodes (iLN), and 
central nervous system (CNS) harvested shortly after peak of disease (n = 8, pooled from two experiments). (a) Mean clinical scores + SEM. (B) Representative dot 
plot for gating of CNS Foxp3+ and Foxp3− CD4+ T cells. (c) Representative plots of αv expression on Treg retrieved from different organs. (D) αv expression levels 
on Treg in comparison to conventional T cells in different organs (n = 4, representative of two experiments). (e) Relative mRNA expression levels of αv in Treg and 
conventional T cells in CNS and spleen of EAE mice. (F) Colitis was induced by injection of naive T cells (Tn) into RAG1−/− mice and curative CD4+ Foxp3+ T cells 
(nTreg) were injected 21 days later (n = 10–14 mice per group, pooled from two experiments). Spleen, mesenteric lymph nodes (mLNs) and colon lamina propria 
(LP) were harvested 8 weeks after disease induction. (g) Histological colitis score. (h) Representative histograms showing αv expression on Foxp3+ and 
Foxp3− CD4+ T cells in the LP of colitis mice. (i) αv expression levels on Treg in comparison to conventional T cells in different organs (n = 4, representative  
of two experiments).
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expression upon re-stimulation with cognate antigen ex vivo 
was comparable between groups (Figure  3E). Similarly, αv 
integrins were not required for Treg suppressive activity in a 
preventive model of T cell transfer colitis. αv−/− Treg co-injected 
with disease-inducing naive CD4+ T cells from Foxp3tm4(YFP/cre)Ayr 
mice were as capable of preventing pathological changes of the 
colon and associated weight loss as control Treg (Figures 3F,G). 
Notably, immunohistochemical staining of Foxp3+ cells dem-
onstrated comparable numbers of control and αv−/− Treg in 
the colon LP of these mice (Figures 3H,I). Collectively, these 
data indicate that Treg αv integrins play no critical role in their 
capacity to limit inflammation initiated by the activities of CD4+ 
T cells.
αv−/− Treg can Migrate to the inflamed 
cns and resolve eae
The integrin αvβ8 has been recently proposed to be essential for 
Treg function at sites of inflammation through the activation 
of latent TGF-β (28). During EAE, CNS Treg exhibit a highly 
activated phenotype (34, 35), and Treg are crucial in mediating 
the resolution of disease (35–37). While αv integrins appeared 
FigUre 2 | Basic characterization of regulatory T cells (Treg) from Foxp3-αv−/− mice. (a) Representative histograms of αv expression in Foxp3+ and Foxp3− CD4+ 
T cells in unmanipulated Foxp3tm4(YFP/cre)Ayr and Foxp3-αv−/− mice. (B) Proportion of αv+ Treg in WT and Foxp3-αv−/− mice (n = 7–10, pooled from three experiments). 
(c) Proportion of Foxp3+ Treg in Foxp3tm4(YFP/cre)Ayr and Foxp3-αv−/− mice (n = 6–7 mice per group, pooled from three experiments). Naive CD4+ T cells from 
Foxp3tm4(YFP/cre)Ayr and Foxp3-αv−/− mice were cultured under iTreg generating conditions and (D) Foxp3 expression assessed over time (n = 6 mice per group,  
pooled from two experiments). iTreg were rested in IL-2 for 2 days and (e) proportion of Foxp3+ iTreg (naive T cells on d0) expressing αv determined over time.
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redundant for Treg homeostasis and Treg-mediated preven-
tion of inflammation, it remained to be determined whether 
the observed elevated levels of αv on CNS Treg (Figures 1C–E) 
had a functional consequence for resolution of EAE. The 
role of αv integrins, and particularly the integrin αvβ8, in 
Treg function during EAE was explored in Foxp3tm4(YFP/cre)Ayr, 
Foxp3-αv−/− and Foxp3-β8−/− mice, following immunization 
with pMOG. The clinical courses and mean maximal EAE 
scores were indistinguishable between all three mouse lines 
(Figures  4A,B), indicating no requirement for αv integrins 
in Treg-dependent resolution of EAE. Shortly after peak of 
disease, αv−/− and β8−/− Treg were found at similar proportions 
in the CNS as WT Treg (Figures 4C,D), excluding a critical 
role for αv integrins in Treg migration into the inflamed 
CNS. CNS Treg in all three mouse lines displayed an effector 
Treg phenotype, with high CD44 and low CD62L expression, 
high cell cycle activity and heightened KLRG1 expression, 
compared to their peripheral counterparts (Figures S4A–C in 
Supplementary Material).
impaired accumulation of αv−/− Treg in the 
inflamed gut and Quantitative Defect to 
cure T cell-induced colitis
Although Treg are critical to the immune processes that ulti-
mately lead to the resolution of EAE, it remains unclear whether 
this non-redundant influence is exerted solely by those Treg that 
accumulate in the inflamed CNS, or whether an alternative, ear-
lier effect of restraining pathogenic T cell expansion during the 
priming stages of EAE in the peripheral lymphoid organs is also 
required, or even indispensable. To more specifically address the 
activity of Treg once inflammatory pathology was established, we 
chose the curative model of T cell transfer colitis, whereby Treg 
are injected into RAG1−/− after disease onset (38), and control of 
colonic inflammation can only occur if Treg migrate to the site 
of inflammation.
T  cell transfer colitis was induced in RAG1−/− mice, and 
Foxp3tm4(YFP/cre)Ayr, αv−/− or β8−/− Treg were injected at 2.5 ×  105 
cells per mouse 21  days later. Both the control Treg-treated 
FigUre 3 | αv-deficient regulatory T cells (Treg) can suppress responder T cell proliferation in vitro and in vivo. (a) Varied numbers of Foxp3tm4(YFP/cre)Ayr or Foxp3-αv−/− 
nTreg were cocultured with a fixed number of Foxp3tm4(YFP/cre)Ayr naive T cells in the presence of irradiated antigen presenting cells and soluble anti-CD3 for 4 days. Cell 
proliferation was measured by 3H-thymidine incorporation in the last 18 h of culture (n = 2–3 mice per group). (B) Foxp3tm4(YFP/cre)Ayr or Foxp3-αv−/− nTreg were cultured 
with mouse T-Activator Dynabeads at a 1:1 ratio for 3 days in the presence of 1,000 U/ml IL-2, and IL-10 concentrations measured in the culture supernatant by 
ELISA (n = 6, pooled from two experiments). Foxp3tm4(YFP/cre)Ayr and Foxp3-αv−/− mice were immunized with pOVA in CFA 1 day after transfer of 2 × 106 CD4+ OT-II 
responder cells (CD45.1), and organs harvested 7 days later. (c) Gating strategy for host (CD45.1−) and donor (CD45.1+) CD4+ T cells and (D) total numbers of donor 
cells retrieved from spleen and inguinal lymph nodes (iLNs). (e) Splenocytes were restimulated with 20 µg/ml pOVA overnight and cytokine expression analyzed by 
intracellular cytokine staining. (F) Colitis was induced by injection of naive T cells (Tn) into RAG1−/− mice in the presence or absence of Foxp3tm4(YFP/cre)Ayr or Foxp3-αv−/− 
nTreg and weight assessed over time (n = 11–12 mice per group, pooled from two experiments). (g) Histological colitis score 6 weeks after disease induction 
(range = 0–11). (h) Colon sections were stained with anti-Foxp3 (see black arrows) and anti-CD3 antibodies and visualized with Vector Blue substrate and DAB, 
respectively. (i) Numbers of Foxp3+ cells were counted in a 2 cm long longitudinal section of the colon, starting 2 cm proximal of the anus (n = 6 per group).
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and the β8−/− Treg-treated mice began regaining weight around 
3 weeks after Treg injection (Figure 5A). However, αv−/− Treg-
treated mice failed to regain weight (Figure 5A), translating into 
no weight gain from the time of Treg injection, compared to mice 
receiving either control or β8−/− Treg (Figure 5B). Consistent with 
this, histological severity of colitis differed significantly between 
FigUre 4 | αv-deficient regulatory T cells (Treg) are able to migrate to the 
inflamed central nervous system (CNS) and resolve experimental autoimmune 
encephalomyelitis (EAE). EAE was induced in Foxp3tm4(YFP/cre)Ayr, Foxp3-αv−/−, 
and Foxp3-β8−/− mice by immunization with pMOG and mice monitored up to 
30 days. (a) Mean clinical scores ± SEM and (B) maximal disease scores 
(n = 18–24 mice per group, pooled from four experiments). EAE was induced 
as above and spleen, inguinal lymph nodes (iLNs), and CNS harvested 
shortly after peak of disease (n = 3–8, pooled from two experiments).  
(c) Mean clinical scores + SEM. (D) Proportion of Treg in indicated organs.
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groups (Figures  5C,D); while mice receiving control Treg and 
β8−/− Treg had relatively low colitis scores, those receiving αv−/− 
Treg had disease scores which did not differ from diseased mice 
that received no Treg treatment. This failure of αv−/− Treg to cure 
colitis was associated with significantly reduced Treg proportions 
and numbers in the LP (Figure 5E; Figure S5A in Supplementary 
Material). In contrast, Treg proportions and numbers in the spleen 
and mLN were not reduced (Figures S5B-E in Supplementary 
Material). However, the proportion of Treg expressing Ki-67 
as well as Foxp3 expression levels of Treg in the LP did not 
differ between groups (Figures  5F,G), suggesting that neither 
reduced Treg proliferation nor Foxp3 instability were the cause 
of the observed lower αv−/− Treg proportions in the LP. Finally, 
at a higher number of curative Treg (8 × 105) injected 21 days 
postdisease induction, control and αv−/− Treg were equally able 
to reverse disease (Figures 6A–C). While a significantly reduced 
proportion of αv−/− Treg in the colon LP was still apparent at 
harvest (Figure  6D), they represented an average 5.4% of the 
colonic CD4+ T cell population versus 2.2% in the first curative 
colitis experiment. This suggests that a quantitative, rather than 
qualitative, deficit was responsible for the observed inability of 
αv−/− Treg to cure colitis at lower Treg injection numbers.
DiscUssiOn
Our findings highlight the tissue- and context-specific require-
ment for Treg αv integrins in optimal Treg function. αv integrins 
were not required for Treg to migrate to the inflamed CNS during 
EAE and resolve disease. Furthermore, αv−/− Treg were able to 
prevent T cell transfer colitis. However, during a curative T cell 
transfer model of colitis, αv−/− Treg were detected at significantly 
lower proportions and numbers in the inflamed gut, and this cor-
related with an impairment in the ability of αv−/− Treg to resolve 
colitis compared to WT Treg.
αv integrins are crucial for Treg 
accumulation in the inflamed gut
The curative model of T  cell transfer colitis is a useful tool to 
assess whether Treg can migrate to the already established site of 
inflammation in the periphery and resolve ongoing inflamma-
tion. When injecting naive CD4+ T cells alone, a small proportion 
of these cells are converted into Foxp3 expressing peripherally 
induced Treg in the gut (39). Mice receiving 2.5 × 105 αv−/− Treg 
showed similar proportions and numbers of Foxp3+ cells in the 
colon LP as control mice that received no Treg injection, associ-
ated with a failure to reverse disease. While injection of a higher FigUre 4 | Continued
FigUre 5 | Regulatory T cells (Treg) lacking all αv integrins are unable to cure T cell-induced colitis due to attenuated accumulation in the inflamed gut. Colitis was 
induced by injection of naive T cells (Tn) into RAG1−/− mice, and 2.5 × 105 nTreg from Foxp3tm4(YFP/cre)Ayr, Foxp3-αv−/−, or Foxp3-β8−/− mice injected 21 days later 
(n = 7–12 mice per group, pooled from two experiments). Spleen, mesenteric lymph nodes (mLN), and colon lamina propria (LP) were harvested 9 weeks after 
disease induction. Weight change (a) over time and (B) at harvest relative to weight at nTreg injection. (c) Histological colitis score (range = 0–11) and  
(D) representative H&E-stained sections of the colon LP. Proportion of (e) Treg and (F) Ki-67+ Treg in the colon LP. (g) Foxp3 expression levels of Treg in the  
colon LP (n = 4–6, representative of two experiments).
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number (8  ×  105) of curative αv−/− Treg resulted in a greater 
proportion of Treg in the colon LP and the ability to resolve 
disease, the deficit in Treg accumulation in the colon in the 
absence of αv compared to WT Treg was still apparent. Integrins 
have been implicated in the migratory capacity of many cell types 
(40). However, subsets of CD4+ T cells do not share all migratory 
pathways, with integrin α4 being critical for Th1 cell entry into 
the CNS during EAE while being redundant for Treg entry (19). 
Instead, Treg rather depend on αL to cross the blood–brain bar-
rier. Mechanisms of Treg migration may also be tissue-specific, 
since Treg found in different tissues have a distinct gene expres-
sion profile, adapted to the respective environment (4, 41–44). It 
is therefore not surprising that in a different experimental model 
of tissue inflammation, namely EAE, αv−/− Treg were found to 
accumulate at expected levels in the inflamed CNS. Overstreet 
et al. reported no role for αv integrins in effector T cell migra-
tion from lymph nodes into the inflamed skin (23). However, 
ECM changes during inflammation promoted a role for αv 
integrins in interstitial movement within the skin, thereby aiding 
clearance of infection. Since αv integrins are able to recognize 
several components of the ECM, a role in controlling migration 
in inflamed versus non-inflamed tissue is conceivable. This is 
further supported by the observation that αv−/− Treg were found 
at comparable levels to control Treg in the colon during the 
FigUre 6 | High numbers of injected αv-deficient regulatory T cells (Treg) allow for disease resolution in T cell-induced colitis. Colitis was induced by injection  
of naive T cells (Tn) into RAG1−/− mice, and 8 × 105 nTreg from Foxp3tm4(YFP/cre)Ayr, Foxp3-αv−/−, or Foxp3-β8−/− mice injected 21 days later (n = 9–13 mice per 
group, pooled from two experiments). Spleen, mesenteric lymph nodes (mLN), and colon lamina propria (LP) were harvested 9 weeks after disease induction. 
Weight change (a) over time and (B) at harvest relative to weight at nTreg injection. (c) Histological colitis score (range = 0–11) and (D) proportion of Treg in  
the colon LP.
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preventive model of T cell transfer colitis. In this model, coinjec-
tion of Treg and naive CD4+ T cells allows for Treg to migrate 
through and populate uninflamed tissue, unlike in the curative 
model. This does not exclude a potential role for αv integrins in 
the survival (10), Foxp3 stability (45), and expansion of Treg (34) 
in the inflamed colon, which have all been implicated in defining 
Treg accumulation in other contexts. Unaltered Treg numbers 
in secondary lymphoid organs and the CNS, in the case of EAE, 
does not preclude the possibility that αv integrins are required 
for Treg survival in the inflamed gut, since different Treg subsets 
have been reported to depend on specific survival signals, such 
as ICOS in the case of effector Treg (10) and IL-2 in the case 
of central Treg (46, 47). While we confirmed comparable Foxp3 
and Ki-67 levels in colonic Treg, arguing against altered Treg 
stability and local expansion, respectively, the data reflect only 
the circumstances of the time point analyzed. However, there is 
strong evidence that αv−/− Treg have no functional deficit in their 
immunosuppressive capacity. This is supported by their ability 
to suppress activation of responder T cells in vitro as well as in 
several in vivo models to the same extent as WT Treg, and their 
equal expression of IL-10 upon activation—a cytokine crucial 
for Treg function in homeostasis (30), EAE (36) and the curative 
T cell transfer colitis model (48). Furthermore, the inability of 
αv−/− Treg to cure colitis was based on their negligible numbers in 
the inflamed colon, with Treg numbers being below a threshold 
that could confer immunosuppression. When a higher number 
of Treg was injected, leading to a relative increase in αv−/− Treg 
found in the colon, Treg numbers appeared sufficient to suppress 
ongoing inflammation and mice recovered from colitis equally, 
whether αv−/− or WT Treg had been injected. In summary, while 
definitive identification of the prevalent mechanism requires fur-
ther investigation, data presented here suggest that αv integrins 
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play an important role in Treg accumulation, but not function, 
specifically in the inflamed gut.
αv integrins are not required for Treg 
Development and immune homeostasis
Despite the severe functional deficiency of Treg in the inflamed gut 
in the absence of αv, conditional Foxp3-αv−/− mice were healthy 
and retained a normal Treg compartment in the steady state, 
including in the colon LP. This indicates that αv integrins are not 
required for Treg development, nor for homing and maintenance 
in the colon under homeostatic conditions. Global knockout of 
αv leads to early lethality in mice due to placental defects and 
defects in brain vasculogenesis leading to intracerebral hemor-
rhages (49). However, this phenotype is not due to lack of αv on 
lymphocytes, since conditional Lck-αv−/− mice did not present 
with spontaneous autoimmune disease (25). We can further con-
firm that lack of αv integrins on Treg did not result in disturbed 
immune homeostasis in mice left to age up until 10 months of 
age. Therefore, αv integrin expression by Treg plays a far minor 
role in immune homeostasis than on DCs; mice lacking αvβ8 
on DCs develop spontaneous colitis (25) due to the inability of 
CD103+ DCs to activate latent TGF-β and thereby induce adap-
tive Treg in the gut (26). We also found no role for αv integrins in 
Treg-mediated control of the initiation of an immune response, 
using an in vitro suppression assay, in vivo priming, and a preven-
tive model of T cell transfer colitis. This highlights the context 
dependency of the functional relevance of Treg αv integrins. 
While αv−/− Treg were capable of migrating to the colon in the 
preventive model of T cell transfer colitis, Treg are not needed in 
the colon to control disease in this model (5). Rather, Treg act on 
responder T cells in the secondary lymphoid organs. In contrast, 
in the curative model, Treg are required to migrate to the inflamed 
colon to resolve ongoing inflammation. Hence, αv integrins are 
dispensable for Treg to control T cell activation either in the steady 
or during the initiation of inflammation in secondary lymphoid 
organs, but are crucial to allow Treg to accumulate specifically in 
the inflamed gut and resolve inflammation.
Regulatory T cells appear not to be a homogenous population 
of cells with consistent regulatory functions. So-called “central” 
Treg are thought to represent a Treg pool responsible to keep 
homeostasis and control T  cell activation in the secondary 
lymphoid organs. These have been characterized by expression 
of CCR7 and CD62L, directing their circulation through the 
lymphoid tissues (10, 17). On the other hand, so called “effec-
tor Treg” are deemed important in controlling inflammation 
in peripheral tissue, and among the markers attributed to this 
functional subgroup are KLRG1 and CD103 (18, 50, 51). Our 
study shows that αv integrins are important for the effector Treg 
function specifically in the context of the inflamed gut, but are 
redundant for the central Treg function of maintaining immune 
homeostasis.
active TgF-β leads to Downregulation  
of αv integrins on cD4+ T cells
During iTreg generation, it was observed that αv surface expres-
sion was lost not only on CD4+ T cells from Foxp3-αv−/− mice, 
but also on WT cells. This prompted further investigation and 
it was found that, in both conventional T  cells and Treg, the 
presence of active TGF-β in the culture medium resulted in 
reduced surface αv levels, attributable at least in part to TGF-β 
signaling. Active TGF-β itself cannot bind to αv integrins, as 
the RGD tripeptide sequence that functions as integrin αv 
binding site is within the latency-associated peptide (52). It can 
therefore be excluded that observed reductions in αv levels are 
an artifact due to blocking of the binding site for the analysis 
antibody by TGF-β. It could be postulated that active TGF-β 
acts as a negative feedback regulator for αv integrin expres-
sion, since they have been implicated in the activation of latent 
TGF-β by a multitude of cell types (22). However, this finding 
stands in contrast to reports that αv integrins are upregulated 
by TGF-β signaling in several cell types including epithelial cells 
(53), keratinocytes (54) and fibroblasts (55, 56). While these 
divergent consequences of TGF-β signaling with respect to αv 
integrin expression deserve further investigation, they may well 
reflect the different biological contexts of TGF-β signaling in 
these cells.
αvβ8 is redundant in Treg Function  
during colitis
Regulatory T  cells lacking integrin β8 showed no impaired 
capacity to reverse colitis. It is therefore notable that we 
could not confirm a reported crucial role for αvβ8, acting 
via activation of latent TGF-β, in this context (28). While we 
did not assess TGF-β activation or signaling, lack of a clini-
cal deficiency when using β8-deficient Treg implies that this 
mechanism is redundant in this setting. Considering the high 
redundancy within αv integrins, with all αv integrins binding 
the RGD tripeptide sequence present in ECM components 
and latent TGF-β, a lack of αvβ8 may well be compensated by 
other αv integrins. We can only speculate on reasons for the 
discrepancy in results, despite having used the same curative 
model of T  cell transfer colitis. Our findings are consistent 
with previous reports in that αvβ8-mediated TGF-β activation 
was not required for the prevention of T  cell induced colitis 
(27, 28). It therefore appears that the requirement of αvβ8-
mediated TGF-β activation is highly context-specific, and 
minor differences in experimental settings or the microbiota 
(57) of the utilized mice may be able to explain the contrasting 
results. Another report further supports this notion, showing 
that αvβ8 was not required in an oral tolerance model, despite 
the fact that Treg-derived TGF-β was crucial for the induction 
of tolerance in that model (58).
αv integrins are not required for Treg 
Migration or Disease resolution in eae
A context-specific role for αv integrins is also highlighted in 
our own findings, since Foxp3-αv−/− mice did not replicate the 
exacerbated and prolonged clinical course of EAE seen in WT 
mice depleted of Treg (35–37). While it is unclear whether Treg 
exert their function solely in the inflamed CNS or whether 
interactions with other immune cells are also important dur-
ing the priming period in the periphery, it is evident from our 
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data that αv integrins are not required for Treg to successfully 
migrate to the CNS and resolve disease. However, it cannot be 
ruled out with certainty that compensatory mechanisms may 
be masking a role for Treg αv integrins in the resolution of 
EAE; such mechanisms in effector T cells have previously been 
reported (23). It should be noted that WT Treg in the inflamed 
CNS exhibited high αv levels, as did WT Treg retrieved from 
the colon during a colitis model. The different functional 
implication of the loss of Treg αv integrins in these two models 
suggests that, at least in the case of αv, Treg change their expres-
sion pattern upon activation in a non-specific manner. This is 
also supported by the heightened αv expression levels in colonic 
Treg under steady state, which are known to display a more 
activated phenotype than their splenic counterparts (59). In 
effector T cells, this indeed appears to be the case, whereby αv 
was shown to be upregulated upon T cell activation in the lymph 
node, rather than at the site of inflammation (23). While an 
individual facet of these apparently global phenotypic changes 
seen among activated Treg may be critical to their function 
in one inflammatory setting, it can be entirely superfluous in 
another. This may be the basis of the high variability of reports 
assessing the functional relevance of specific gene expression 
changes in Treg, such as the highly debated role of T-bet expres-
sion in Treg function (8, 9, 12, 60, 61).
conclusion
In summary, our data provide evidence for a role of αv integrins in 
the successful accumulation of Treg in the inflamed colon, which 
is required for disease resolution. However, we did not identify 
αvβ8 as the integrin specifically required for resolution of colitis, 
indicating redundancy across the αv integrins. The superfluous 
role of αv integrins in Treg-dependent resolution of CNS inflam-
mation highlights the necessity to unravel Treg mechanisms of 
action for individual diseases in order to target Treg successfully 
during inflammatory disease.
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